Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran for Prevention of Postoperative Complications After Off-pump CABG
ChiCTR2500114213Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of inclisiran in coronary arteriosclerosis (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Incidence of adverse cardiovascular and cerebrovascular events within three months and 3-month graft patency rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
inclisiran
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2500114213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114213.